FCGR3A and neoplasm: Finally, Kerbauy and colleagues successfully targeted CD30+ tumor cells with an AFM13 BiKE construct utilized for complex CD30 expressed by lymphoma or leukemia cells with CD16+CB-NK cells while testing the influence of prior NK cell activation with IL-15 in vitro and in vivo [24,74].